Study reveals high dropout rates for GLP-1 weight loss and diabetes drugs within a year
A new study shows that many people stop using GLP-1 weight loss and diabetes drugs within a year. About 65% of patients without diabetes quit, while 46% of those with Type 2 diabetes discontinue use. Cost and side effects are major reasons for stopping. Noom is laying off staff to focus on its GLP-1 products, which include popular drugs like Ozempic and Wegovy. The company aims to enhance its offerings in this growing market, which could become a $100 billion industry by the end of the decade. Compounded GLP-1 medications offered by Noom are cheaper than branded versions, costing $149 for the first month and $279 thereafter. This shift reflects a broader trend among digital health companies responding to increased demand for these medications.